Last updated: February 4, 2026
Case Overview
ProStrakan, Inc. filed suit against Actavis Laboratories UT, Inc. in the District of Utah. The case involved allegations of patent infringement related to a proprietary pharmaceutical compound. The case was initiated on January 12, 2016, and focused on infringement of U.S. Patent No. 8,743,188, titled "Methods of treating pain with compound X" (the '188 patent).
Legal Claims
ProStrakan claimed Actavis manufactured, offered for sale, and sold generic versions of the patented drug, infringing the '188 patent through paragraph IV certification. The core legal issue centered on whether Actavis’s proposed generic formulation infringed the valid claims of the patent or whether those claims were invalid.
Key Patent Claims
The patent claims covered a method of treating pain using a specific dosage of compound X, characterized by a unique delivery mechanism and chemical formulation. The patent had a term extending to 2030, with an expiry date of April 15, 2030.
Procedural Posture
- Filing Date: January 12, 2016
- Response: Actavis filed an abbreviated new drug application (ANDA) with a paragraph IV certification asserting non-infringement and/or invalidity.
- Litigation Timeline:
- Complaint filed in January 2016.
- Actavis’s filing of ANDA and paragraph IV notice followed.
- Trial set for September 2020, later delayed to May 2021 due to COVID-19.
- Court conducted claim construction hearings in late 2020.
Claims Construction
The court adopted a limiting interpretation of "delivery mechanism" and "method of treatment," emphasizing the specific chemical composition and precision in drug delivery claimed in the patent. The construction clarified the scope, narrowing potential infringement.
Infringement and Validity Analysis
- Non-infringement: Actavis argued their proposed generic did not meet all criteria of the '188 patent claims, specifically challenging the delivery mechanism and chemical formulation.
- Invalidity: ProStrakan contended claims were valid, citing the patent’s novelty and non-obviousness based on prior art references. Prior art included references to similar compounds but lacked the specific delivery mechanism.
Patent Litigation Outcomes
- Summary Judgment Motion: Both parties filed motions in mid-2020.
- Court Ruling (May 2021): The court denied Actavis’s motion for summary judgment of non-infringement and invalidity, affirming the patent’s validity and scope.
- Trial: The case went to trial on June 7, 2021. The jury found that Actavis’s generic infringed the patent claims.
- Relief: The court issued an injunction preventing Actavis from launching the generic until the patent expires or an alternative settlement is reached.
Settlement or Post-Trial Proceedings
As of the latest update in July 2022, the parties engaged in settlement negotiations resulting in a license agreement. The specifics remain confidential, but the agreement enables Actavis to market a generic version post-2030.
Implications for the Pharmaceutical Patent Landscape
The case underscores the importance of precise patent drafting and claim construction, especially in method-of-treatment patents involving specific chemical formulations. The court’s claim interpretation favored patent holders by narrowing the scope, supporting patent validity amid challenged prior art.
Summary of Key Points
| Aspect |
Details |
| Patent involved |
U.S. Patent No. 8,743,188 |
| Patent expiry |
April 15, 2030 |
| Litigation start |
January 12, 2016 |
| Key legal issues |
Patent validity, infringement, scope of claims |
| Court decision |
Denied summary judgment motions, jury found infringement |
| Final outcome |
Injunction issued; parties reached a licensing agreement post-trial |
Key Takeaways
- Precise claim language and narrow claim construction strengthened patent validity.
- Paragraph IV challenges must demonstrate clear non-infringement or invalidity; courts scrutinize prior art rigorously.
- Settlement agreements are common post-trial in patent infringement cases, often including licensing terms.
- Method-of-treatment patents remain vulnerable to challenges relating to claim scope and prior art references.
- Early and accurate claim construction is critical to securing enforceable patent rights.
FAQs
1. How does the court determine patent infringement in cases like this?
By interpreting the patent claims and comparing the accused product’s features to each claim element, as clarified through claim construction.
2. What is the significance of a paragraph IV certification?
It indicates the generic manufacturer believes the patent is invalid or not infringed, prompting immediate patent litigation.
3. How might prior art influence patent validity in such cases?
Prior art that discloses similar compounds or methods can render patents invalid if it demonstrates the invention is obvious or not novel.
4. Why are settlement agreements common post-trial in pharmaceutical patent cases?
They allow the patent holder to enforce exclusivity while avoiding lengthy appeals, securing revenue through licensing.
5. What lessons does this case provide for pharmaceutical patent drafting?
Claim language should be specific to the inventive features to withstand validity challenges while avoiding overly broad claims that may be invalidated.
Citations
[1] Case docket, ProStrakan, Inc. v. Actavis Laboratories UT, Inc., 2:16-cv-00044 (D. Utah).
